Irritable Bowel Syndrome
Research activity is centred on irritable bowel syndrome, with particular attention to the diarrhoea-predominant form (IBS-D) and its burden of persistent gastrointestinal symptoms.
- IBS-D symptom control
- Frequency and severity of bowel symptoms
- Gastrointestinal tolerability
The sponsor’s clinical interest in this area is focused on oral treatment approaches for patients with functional bowel disorders.
Microbiome-Related Gastrointestinal Therapy
The trial portfolio includes work on a live bacterial oral product for gastrointestinal symptom management, reflecting interest in microbiome-based therapy for functional digestive conditions.
- Live bacterial therapy
- Oral gastrointestinal treatment
- Functional bowel disorder support
This area aligns with therapeutic development for symptoms associated with altered bowel function and digestive discomfort.
Safety and Tolerability
Clinical interest extends to the assessment of safety and tolerability in patients receiving treatment for chronic digestive symptoms.
- Safety profile evaluation
- Tolerability in IBS-D
- Patient treatment acceptability
These topics are relevant to the clinical use of therapies intended for ongoing management of functional bowel symptoms.
Multicentre Clinical Research
The sponsor’s research footprint includes collaboration across multiple sites in Germany, supporting clinical evaluation in a real-world patient population with IBS.
- Multi-site patient recruitment
- Gastroenterology-focused collaboration
- Clinical assessment in adult IBS populations
Current activity is concentrated on a single recruiting study within the field of digestive health.
